Navigation Links
InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
Date:5/20/2009

InVitria’s BioProcess Theater presentation, “New Strategies for Optimizing CHO Performance,” to feature new supplement for CHO cell culture optimization called ZAP-CHO during BIO 2009 International Convention in Atlanta, GA. 

Fort Collins, CO May 19, 2009 / b3c newswire / – InVitria’s Director of Cell Culture, Dr. Steve Pettit, will present the performance enhancing features of ZAP-CHO, a new media component for Chinese hamster ovary (CHO) cell culture, at 3:30 pm on Wednesday, May 20, 2009 as part of BioProcess International’s BioProcess Theatre, a venue employed to facilitate the sharing of advances and discoveries in the biopharmaceutical sector.  

ZAP-CHO, a new product from InVitria, enhances performance of mammalian cell culture including improved cell growth and antibody production. It achieves these performance advantages in chemically defined media that are completely free of animal components. Previously, the performance seen with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum), BSA (bovine serum albumin) or plasma-derived HSA (human serum albumin) in cell culture media.

“Our team of scientists has developed supplements that not only meet the regulatory requirements of researchers using hybridoma and CHO cell culture, but it exceeds their performance expectations as well,” said Dr. Pettit. “InVitria products have been utilized by customers to successfully achieve greater cell productivity and growth; faster cell doublings; and improved consistency.”

InVitria’s other leading cell culture media supplements will also be part of the BIO Process Product Zone exhibition in Booth #5120 within the BIO 2009 International Convention from May 19-21.  These supplements include:
* Albumin-DX—whether you have problems with non-specific binding, biomarker stability, consistency or regulatory requirements, Albumin-DX was designed to answer the most difficult assay challenges.
* Cellastim—Cellastim outperforms plasma-derived albumin, bovine serum albumin and other sources of recombinant albumin.
* Lacromin—Lacromin is a CHO growth-factor that outperforms insulin and IGF-1.


About InVitria - www.InVitria.com

InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

Contact
Erik H. Vogel
InVitria
Marketing Manager
Phone: 1-800-916-8311
info@InVitria.com
www.InVitria.com


'/>"/>
b3c newswire

Related biology news :

1. InVitria Announces Launch of Recombinant Albumin for Diagnostics
2. Unveiling the structure of microcrystals
3. EC unveils new EU maritime policy
4. Scientists unveil structure of molecular target of many drugs
5. Tumor genome analysis unveils new insights into lung cancer
6. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
7. Research unveils new hope for deadly childhood disease
8. LTER unveils a new decadal science plan
9. Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition
10. Unveiling the underwater ways of the white shark
11. Washington University unveils draft sequence of corn genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today is providing ... its previously announced rights offering of up to ... stock and Series C Convertible Preferred Stock to ... As previously announced, the rights offering ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive ... 2014, FireflySci had the goal of bringing their powerful cuvette and spectrophotometer ... the path that FireflySci is going on as they add yet another mark on ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
Breaking Biology Technology: